Vaxcyte Inc (PCVX) Stock Price, Quote & News

Company Profile

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conju...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 837 0111

Website: vaxcyte.com

Address:

825 Industrial Road, Suite 300, San Carlos, United States

BioTechHealthX Jun. 22 at 4:17 AM

$PCVX Discover how Vaxcyte’s revolutionary vaccine technology and massive market potential make PCVX one of the best stocks of 2025. https://biotechhealthx.com/biotech-news/vaxcyte-pcvx-could-be-the-next-biotech-giant-in-the-vaccine-industry/

0 · Reply

bulldoglane Jun. 9 at 1:39 PM

$PCVX 40 coming anytime

0 · Reply

BIG_STOCKY Jun. 9 at 12:58 PM

$PCVX IS THIS DAMN THING EVER GOING TO HIT $40 AGAIN?

0 · Reply

swingingtech Jun. 5 at 12:58 PM

$ESML $PCVX $NRIX $MNKD https://wallstreetwaves.com/esml-projected-to-reach-48-based-on-mathematical-analysis/

0 · Reply

Washingtonstate Jun. 2 at 7:49 PM

$PCVX

0 · Reply

theCATALYST May. 29 at 8:12 PM

$ARVN $PCVX $SLDB +12% / +1% / +7%

0 · Reply

Night_Owl_Biotech May. 27 at 6:49 PM

Biopharma investing can be brutal. If anyone can explain $TVTX as the AdCom was announced on 5/15/25 as was the PDUFA extension at $BHVN? $PCVX $VERA $RVMD there appears nothing...then why?

1 · Reply

theCATALYST May. 27 at 3:56 PM

Re-added and/or added more in my Roth; $ARVN $PCVX $SLDB

0 · Reply

Stmkr May. 24 at 4:43 AM

$CDTX $PCVX is currently valued at around $4B for its pneumococcal vaccine, which btw faces fierce competition. Imagine the value of $CDTX after a positive ph2b next month! (1) CD388 will be the ONLY product that offers UNIVERSAL protection against ALL flu strains and in ALL patients (even those that can not ammount a proper immune response to vaccine) (2) CD388 is NOT a vaccine, but a long-acting (single dose for whole season) antiviral (3) I dont know if/when another flu pandemic is coming, but you can all guess what will happen to CDTX price in such a scenario. Even just for pandemic preparedness I see a high potential for good revenue. Obviously, CDTX will need cash for a ph3 (easy after a positive ph2b). CDTX also has an oncology pipeline (currently paused, but easily to be revived after a positive ph2b for flu)

0 · Reply

approved_13 May. 20 at 4:45 PM

$PCVX

0 · Reply

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:00 AM EDT - 7 weeks ago

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

Mar 31, 2025, 6:21 PM EDT - 2 months ago

Vaccine stocks fall following FDA resignation

BNTX MRNA NVAX PFE PTCT XBI

Mar 31, 2025, 3:39 PM EDT - 3 months ago

Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity

Mar 31, 2025, 8:56 AM EDT - 3 months ago

Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine

Mar 31, 2025, 7:00 AM EDT - 3 months ago

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

Mar 30, 2025, 5:00 PM EDT - 3 months ago

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

Feb 26, 2025, 3:26 AM EST - 4 months ago

Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:01 PM EST - 4 months ago

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 12, 2025, 4:05 PM EST - 4 months ago

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Feb 5, 2025, 8:00 AM EST - 4 months ago

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Jan 30, 2025, 4:05 PM EST - 5 months ago

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 11:51 AM EST - 5 months ago

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Jan 15, 2025, 7:15 AM EST - 5 months ago

Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy

PFE

Dec 3, 2024, 8:00 AM EST - 7 months ago

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Nov 12, 2024, 7:30 AM EST - 7 months ago

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Nov 5, 2024, 4:01 PM EST - 8 months ago

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 11, 2024, 4:05 PM EDT - 10 months ago

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

Sep 8, 2024, 9:00 AM EDT - 10 months ago

Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027

Sep 6, 2024, 4:05 PM EDT - 10 months ago

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 6, 2024, 3:07 PM EDT - 10 months ago

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Sep 6, 2024, 9:07 AM EDT - 10 months ago

Vaxcyte's stock dips after biotech completes $1.42 billion stock offering

Sep 5, 2024, 1:22 AM EDT - 10 months ago

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Sep 4, 2024, 11:58 PM EDT - 10 months ago

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Sep 3, 2024, 4:01 PM EDT - 10 months ago

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Sep 3, 2024, 10:48 AM EDT - 10 months ago

Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.

Sep 3, 2024, 10:10 AM EDT - 10 months ago

Vaxcyte stock soars 35% on promising VAX-31 vaccine trial results

Sep 3, 2024, 9:24 AM EDT - 10 months ago

Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine

Sep 3, 2024, 8:51 AM EDT - 10 months ago

Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine

Sep 3, 2024, 7:07 AM EDT - 10 months ago

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Sep 2, 2024, 6:40 PM EDT - 10 months ago

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Vaxcyte Appoints John Furey to Board of Directors

May 8, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 2, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 4, 2024, 8:30 AM EST - 1 year ago

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Feb 28, 2024, 12:32 AM EST - 1 year ago

Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 4:01 PM EST - 1 year ago

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 15, 2024, 4:05 PM EST - 1 year ago

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Feb 2, 2024, 6:39 PM EST - 1 year ago

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 1, 2024, 4:05 PM EST - 1 year ago

Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 30, 2024, 11:37 PM EST - 1 year ago

Vaxcyte Announces Pricing of $750 Million Public Offering

Jan 29, 2024, 8:30 AM EST - 1 year ago

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

Jan 16, 2024, 4:01 PM EST - 1 year ago

Vaxcyte Appoints Whitney Jones as Chief People Officer

Jan 4, 2024, 4:01 PM EST - 1 year ago

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

Dec 4, 2023, 6:35 PM EST - 1 year ago

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Nov 28, 2023, 8:30 AM EST - 1 year ago

Vaxcyte Appoints Jacks Lee to Board of Directors

Nov 27, 2023, 4:00 PM EST - 1 year ago

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

Nov 9, 2023, 8:30 AM EST - 1 year ago

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Nov 6, 2023, 4:03 PM EST - 1 year ago

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

BioTechHealthX Jun. 22 at 4:17 AM

0 · Reply

bulldoglane Jun. 9 at 1:39 PM

$PCVX 40 coming anytime

0 · Reply

BIG_STOCKY Jun. 9 at 12:58 PM

$PCVX IS THIS DAMN THING EVER GOING TO HIT $40 AGAIN?

0 · Reply

swingingtech Jun. 5 at 12:58 PM

$ESML $PCVX $NRIX $MNKD https://wallstreetwaves.com/esml-projected-to-reach-48-based-on-mathematical-analysis/

0 · Reply

Washingtonstate Jun. 2 at 7:49 PM

$PCVX

0 · Reply

theCATALYST May. 29 at 8:12 PM

$ARVN $PCVX $SLDB +12% / +1% / +7%

0 · Reply

Night_Owl_Biotech May. 27 at 6:49 PM

Biopharma investing can be brutal. If anyone can explain $TVTX as the AdCom was announced on 5/15/25 as was the PDUFA extension at $BHVN? $PCVX $VERA $RVMD there appears nothing...then why?

1 · Reply

theCATALYST May. 27 at 3:56 PM

Re-added and/or added more in my Roth; $ARVN $PCVX $SLDB

0 · Reply

Stmkr May. 24 at 4:43 AM

0 · Reply

approved_13 May. 20 at 4:45 PM

$PCVX

0 · Reply

Dr_Stoxx May. 20 at 4:35 PM

Some in our LIVE ROOM are long $PCVX. I had shares myself but sold most on the pop. If this base breaks out, it could get really interesting.

0 · Reply

Dr_Stoxx May. 19 at 4:22 PM

The stock in question here? $PCVX

1 · Reply

Dr_Stoxx May. 16 at 4:14 PM

$PCVX: beaten down drugger just triggered another price alert today. We bought shares yesterday morning on the first alert, 29.60, in the LIVE TRADING ROOM. Not investment grade, just a fun money swing trade.

0 · Reply

Dr_Stoxx May. 15 at 7:10 PM

$PCVX: small-floater biotech play off the lows getting some love today. We nibbled on a lotto today in the Live Trading Room.

0 · Reply

approved_13 May. 15 at 1:32 PM

$PCVX this is gonna go just matter of time….

0 · Reply